ClinicalTrials.Veeva

Menu

Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)

Organon logo

Organon

Status and phase

Completed
Phase 3

Conditions

Migraine

Treatments

Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1 day
Drug: Comparator: placebo / Duration of Treatment - 1 day

Study type

Interventional

Funder types

Industry

Identifiers

NCT00111709
0462-071
2005_024

Details and patient eligibility

About

The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.

Enrollment

393 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female patient at least 18 years old
  • Patient has menses approximately monthly
  • Patient has at least a 5 month history of migraine and at least a 6 month history of menstrual migraine

Exclusion criteria

  • Pregnant and/or nursing
  • Cardiovascular disease
  • Uncontrolled hypertension

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems